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Abstract
Aims: To evaluate short-term clinical outcomes following transcatheter aortic valve implantation (TAVI) 
using CE-mark approved devices in Switzerland.
Methods and results: The Swiss TAVI registry is a national, prospective, multicentre, monitored cohort 
study evaluating clinical outcomes in consecutive patients undergoing TAVI at cardiovascular centres in 
Switzerland. From February 2011 to March 2013, a total of 697 patients underwent TAVI for native aortic 
valve stenosis (98.1%), degenerative aortic bioprosthesis (1.6%) or severe aortic regurgitation (0.3%). 
Patients were elderly (82.4±6 years), 52% were females, and the majority highly symptomatic (73.1% NYHA 
III/IV). Patients with severe aortic stenosis (mean gradient 44.8±17 mmHg, aortic valve area 0.7±0.3 cm2) 
were either deemed inoperable or at high risk for conventional surgery (STS 8.2%±7). The transfemoral 
access was the most frequently used (79.1%), followed by transapical (18.1%), direct aortic (1.7%) and sub-
clavian access (1.1%). At 30 days, rates of all-cause mortality, cerebrovascular events and myocardial infarc-
tion were 4.8%, 3.3% and 0.4%, respectively. The most frequently observed adverse events were access-related 
complications (11.8%), permanent pacemaker implantation (20.5%) and bleeding complications (16.6%). 
The Swiss TAVI registry is registered at ClinicalTrials.gov (NCT01368250).
Conclusions: The Swiss TAVI registry is a national cohort study evaluating consecutive TAVI procedures in 
Switzerland. This first outcome report provides favourable short-term clinical outcomes in unselected TAVI 
patients.
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Introduction
Aortic valve stenosis is the most clinically relevant valvular heart 
disease in the elderly patient population and is associated with 
worse clinical outcomes once symptoms occur1. Surgical aortic 
valve replacement (SAVR) was for decades the standard treatment 
for patients with symptomatic, severe aortic stenosis, and resulted 
in effective alleviation of symptoms, improvement of health-related 
quality of life and overall prognosis2. Following the introduction of 
transcatheter aortic valve implantation (TAVI) in 2002 as a less 
invasive treatment for symptomatic severe aortic stenosis3, TAVI 
has evolved into a reliable therapeutic alternative with comparable 
results to SAVR in well-defined patient subgroups4-6. Currently, the 
indication for TAVI is limited to carefully selected patients deemed 
inoperable or at excessive risk for SAVR2. A successful TAVI pro-
cedure is preceded by a complex selection process of patients, 
requiring detailed imaging information of the aortic valve anatomy 
and the peripheral vasculature, and also a meticulous clinical 
assessment by an interdisciplinary Heart Team7,8.
In the era of the Heart Team, the Swiss Working Group of 
Interventional Cardiology in collaboration with the Swiss Society 
of Cardiac Surgery started a nationwide, prospective cohort study 
in 2011, with the intention of assessing the safety and efficacy of 
unselected and consecutive TAVI procedures in Switzerland. As the 
first TAVI in Switzerland was performed in August 2007, this registry 
mainly focuses on contemporary results of experienced cardiovascu-
lar centres in consecutive patients treated with TAVI in Switzerland.
Methods
The Swiss TAVI registry is a national, prospective cohort study 
aiming for consecutive patient enrolment, data monitoring and end-
point adjudication by a dedicated clinical events committee accord-
ing to the recommendations of the Valve Academic Research 
Consortium (VARC)9,10. The Swiss TAVI registry was designed to 
provide short-term clinical outcomes and long-term clinical data of 
TAVI patients treated with CE-approved devices.
The aim of the present report was to describe the clinical and pro-
cedural characteristics of patients treated with TAVI in Switzerland 
using different CE-approved devices and various access routes as 
well as to stratify short-term outcomes according to device type and 
access route. The study protocol was approved by the local cantonal 
ethics committee at each participating centre and all patients pro-
vided written informed consent. The Swiss TAVI registry is per-
formed under the lead of the Swiss Cardiovascular Centre Bern at 
Bern University Hospital in cooperation with the Clinical Trials 
Unit Bern responsible for data management and independent statis-
tical analysis.
Patient population
A total of 697 patients were enrolled into the Swiss TAVI registry 
between February 2011 and March 2013, and eight centres partici-
pated during this first period of inclusion. Consecutive patient 
enrolment was mandatory. All participating centres are listed in the 
Online Appendix.
Patients were eligible for inclusion in case of symptomatic, 
severe aortic stenosis, degenerated aortic bioprosthesis or severe 
aortic regurgitation treated with CE-approved TAVI devices. Patient 
screening and selection was recommended to be performed within 
a multidisciplinary Heart Team using detailed clinical and anatomi-
cal imaging information. The exclusion criterion for participation in 
the cohort study was the absence of cardiac surgery on-site.
Procedure and devices
Transcatheter aortic valve procedures were performed using 
CE-approved devices only. During the inclusion period, the following 
CE-approved devices were available in Switzerland and used for patient 
treatment: Medtronic CoreValve® (Medtronic Inc., Minneapolis, MN, 
USA), Edwards SAPIEN XT (Edwards Lifesciences, Irvine, CA, 
USA), Symetis Acurate TA™ (Symetis, Lausanne, Switzerland), 
JenaValve (JenaValve Technology GmbH, Munich, Germany) and the 
Portico™ THV (St. Jude Medical, Minneapolis, MN, USA). There was 
no pre-specified recommendation regarding access route selection, and 
the decision as to general anaesthesia or conscious sedation was left to 
the discretion of the Heart Team and according to local expertise. In 
addition, there was no specific recommendation for the type and dura-
tion of antiplatelet or antithrombotic medication, which was left to the 
discretion of the operator and according to local expertise.
Definitions and endpoints
The primary study endpoint with respect to procedural safety was 
all-cause mortality at 30 days of follow-up. Secondary outcome 
measures included cardiovascular mortality, cerebrovascular 
events, myocardial infarction, bleeding complications, vascular or 
access-related complications and acute kidney injury. Serious 
adverse events were site reported and checked for plausibility. All 
events were adjudicated by a clinical events committee, consisting 
of interventional cardiologists and cardiac surgeons according to 
the standardised endpoint definitions proposed by the Valve 
Academic Research Consortium (VARC)9.
Data collection and quality control
Data were collected using standardised case-report forms available 
on a web-based database (www.swisstaviregistry.ch). The database 
was maintained by the Clinical Trials Unit at the University of 
Bern. Apart from baseline, procedural and in-hospital characteris-
tics, the Swiss TAVI registry prospectively collects follow-up data 
at 30 days, 12 months and also after three and five years following 
the procedure. Follow-up was performed individually by each cen-
tre on the basis of phone calls or clinical visits. Central monitoring 
by an independent monitor and statistician was performed to verify 
completeness and accuracy of data entry at each site. Monitoring 
included all patients; however, no on-site monitoring or patient data 
validation was performed.
Statistical analysis
Continuous data are reported as mean ± standard deviation (SD), 
and categorical variables are reported as number of patients (% of 
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patients) where appropriate. In-hospital events are reported as 
counts of first occurrence per (sub-) type of event (% of all patients). 
Thirty-day event rates are reported using time-to-first-event data, 
graphically presented using Kaplan-Meier curves, with incidence 
rates calculated from life tables. Event rates at 30 days were com-
pared for patients treated with transvascular vs. surgical access, and 
also within transfemoral patients comparing the two main devices 
Medtronic CoreValve and Edwards SAPIEN XT bioprosthesis, 
using Cox’s regressions. Reported are crude hazard ratios (HR; 
with 95% confidence intervals) with p-value from Wald chi-square 
test, or continuity corrected risk ratios (RR; 95% CI) with p-value 
from Fisher’s exact test in case of zero events. Reported are adjusted 
HR (95% CI), where groups are compared including adjustment for 
age, gender, previous cardiac surgery, peripheral vascular disease, 
and coronary artery disease. Two-sided p-values <0.05 were con-
sidered statistically significant. All analyses were performed with 
Stata version 12 (StataCorp, College Station, TX, USA).
Results
PATIENT POPULATION
A total of 697 patients underwent TAVI between February 2011 
and March 2013 for native aortic valve stenosis (98.1%), degen-
erative aortic bioprosthesis (1.6%) and native aortic regurgitation 
(0.3%) and were entered in the Swiss TAVI registry. Elective treat-
ment was performed in 94.9% of cases, while 5.1% of patients 
underwent urgent or emergent intervention due to haemodynamic 
instability. A multidisciplinary decision for TAVI was reached in 
97.0% of procedures. Mean age was 82.4±6.2 years and 51.5% 
were female. Patients were highly symptomatic, with 73.1% pre-
senting in NYHA functional Class III and IV. The mean aortic valve 
area was 0.74±0.3 cm2 and the transvalvular mean gradient was 
44.8±17.4 mmHg. Patients were considered to be at high surgical 
risk or inoperable with an estimated risk of mortality at 30 days of 
20.2±12.7% according to the logistic EuroSCORE and 8.2±7.1% 
according to the STS score. Detailed information on baseline clini-
cal characteristics are summarised in Table 1.
PROCEDURAL CHARACTERISTICS AND RESULTS
Procedural characteristics and results are presented in Table 2. 
Most TAVI procedures were performed in the catheterisation labo-
ratory (74.6%), the hybrid room (24.2%), and the operating room 
(1.1%) using either general anaesthesia (54.6%) or conscious seda-
tion (45.4%). Transfemoral implantation was performed in 79.1%, 
transapical in 18.1%, the direct aortic access was used in 1.7% and 
the subclavian approach in 1.1%, respectively. The majority of 
patients received balloon aortic valvuloplasty prior to valve inser-
tion (86.7%).The Medtronic CoreValve was implanted in 48.4%, 
the Edwards SAPIEN XT in 45.7%, JenaValve in 3.3%, the Symetis 
Acurate TA in 2.4%, and the Portico THV prosthesis in 0.1% of 
patients. Most patients received only one prosthesis (95.5%); how-
ever, more than one prosthesis was required in 4.5% of patients dur-
ing the intervention. A total of three patients (0.4%) did not receive 
any TAVI prosthesis: one patient was treated with balloon aortic 
Table 1. Baseline characteristics.
 
 
All patients
N=697
Age (years) 82.4±6.2
Female gender, n (%) 359 (51.5)
Body mass index (kg/m2) 26.3±5.0
Cardiac risk 
factors
Diabetes mellitus, n (%) 204 (29.3)
Dyslipidaemia, n (%)  387 (55.5)
Hypertension, n (%) 574 (82.4)
Past 
medical 
history
Previous pacemaker implantation, n (%) 69 (9.9)
Previous myocardial infarction, n (%) 105 (15.1)
Previous cardiac surgery, n (%) 104 (14.9)
Previous stroke, n (%) 83 (11.9)
Clinical 
features
Peripheral vascular disease, n (%) 137 (19.7)
Chronic obstructive pulmonary disease, 
n (%) 109 (15.6)
Coronary artery disease, n (%) 390 (56.0)
Left ventricular ejection fraction (%) 53.8±14.1
Aortic valve area (cm2) 0.74±0.3
Mean transaortic gradient (mmHg) 44.8±17.4
Symptoms 
on 
admission
New York Heart Association (NYHA) functional class
NYHA I or II, n (%)  186 (26.9)
NYHA III or IV, n (%) 505 (73.1)
Canadian Cardiovascular Society (CCS) angina class
No angina, n (%)  496 (71.2)
CCS I or II, n (%)  114 (16.4)
CCS III or IV, n (%)  87 (12.5)
Risk 
assessment
Log. EuroSCORE (%)  20.2±12.7
STS score (%)  8.2±7.1
valvuloplasty only, one patient was converted to surgical aortic 
valve replacement due to heavy calcification of the native aortic 
valve, and one patient died following balloon aortic valvuloplasty 
and prior to any valve insertion. Conversion to surgery occurred in 
0.9% of patients.
Information on the in-hospital course after TAVI is provided in 
Table 3. Cumulative mean duration of hospital length of stay was 
10.7±6.1 days, comprising 1.1±2.4 days in the intensive care unit, 
2.5±2.9 days in the intermediate or coronary care unit and on aver-
age 7.1±5.3 days in the general ward. The majority of patients were 
discharged to a rehabilitation clinic (43.5%), while one third of 
patients (28.9%) were discharged home and another quarter of 
patients were sent back to the referring hospital (24.1%).
CLINICAL OUTCOMES
Short-term clinical outcomes within the first 30 days after TAVI are 
presented in Table 4 (In-hospital clinical outcomes are provided in 
Online Table 1). Cumulative all-cause mortality was 4.8%. All 
deaths were due to cardiovascular causes. The overall rate of cere-
brovascular accidents after 30 days was 3.3% with the majority 
being major strokes (2.5%). The myocardial infarction rate was less 
4 EuroIntervention 2
0
14
; 9
-online publish-ahead-of-print A
p
ril 2
0
14
than 1%. TAVI was effective in symptomatic alleviation (Figure 1) 
showing a reduction of dyspnoea from 73.1% of patients in NYHA 
Class III/IV at baseline to 11.0% at 30-day follow-up. Two main 
subanalyses were performed:
Transvascular (transfemoral and transsubclavian) versus surgical 
access (transapical and transaortic): baseline and procedural char-
acteristics according to access route are provided in the Online 
Table 2. Procedural characteristics.
All patients 
N=697
Procedure time (min) 75.8±37.9
Amount of contrast (ml) 215.0±107.5
General anaesthesia, n (%) 380 (54.6%)
Conversion from local to general anaesthesia, n (%) 16 (5.1%)
Procedure 
location
Catheterisation laboratory, n (%) 520 (74.6%)
Operating room, n (%) 8 (1.1%)
Hybrid room, n (%) 169 (24.2%)
Access site 
location
Femoral, n (%) 551 (79.1%)
Apical, n (%) 126 (18.1%)
Subclavian, n (%) 8 (1.1%)
Direct aortic, n (%) 12 (1.7%)
Concomitant 
procedure
Percutaneous coronary 
intervention, n (%) 65 (9.3%)
Device features Prior balloon aortic 
valvuloplasty, n (%) 604 (86.7%)
Device implanted  
Medtronic CoreValve, n (%) 336 (48.4%)
Edwards SAPIEN XT, n (%) 317 (45.7%)
Symetis Acurate, n (%) 17 (2.4%)
JenaValve, n (%) 23 (3.3%)
SJM Portico, n (%) 1 (0.1%)
Aortic 
regurgitation 
post TAVI
Grade 0, n (%) 170 (24.9%)
Grade 1, n (%) 452 (66.3%)
Grade 2, n (%) 55 (8.1%)
Grade 3, n (%) 5 (0.7%)
%
100
80
60
40
20
0
Baseline 30-day follow-up Baseline 30-day follow-up
Dyspnoea
NYHA functional class
%
100
80
60
40
20
0
Angina
Canadian Cardiovascular Society class
Deceased
NYHA IV
NYHA III
NYHA II
NYHA I
Deceased
CCS4
CCS3
CCS2
CCS1
CCS0
Figure 1. Symptom status at baseline evaluation and at 30-day 
follow-up after TAVI.
Table 3. In-hospital course.
All patients 
N=697
Permanent pacemaker implantation, n (%) 137 (19.9%)
Any PRBC infusion during hospitalisation, n (%) 131 (18.9%)
Number of PRBC, median (interquartile range) 2.0 (1.0; 3.0)
Overall in-hospital stay after TAVI (days) 10.7±6.1
Stay at intensive care unit (days) 1.1±2.4
Stay at intermediate care (days) 2.5±2.9
Stay at general ward (days) 7.1±5.3
Patient 
discharged 
to
Home, n (%) 197 (28.9%)
Referring hospital, n (%) 164 (24.1%)
Rehabilitation clinic, n (%) 296 (43.5%)
Nursing home, n (%) 6 (0.9%)
Other, n (%) 18 (2.6%)
Medication Aspirin exclusive, n (%) 67 (10.4%)
Clopidogrel exclusive, n (%) 14 (2.2%)
Oral anticoagulation exclusive, n (%) 54 (8.4%)
Aspirin and clopidogrel, n (%) 355 (55.0%)
Aspirin and oral anticoagulation, n (%) 71 (11.0%)
Clopidogrel and oral anticoagulation, 
n (%) 38 (5.9%)
Table 4. Clinical outcomes at 30 days.
All patients 
N=697
Mortality, n (%) 33 (4.8)
Cardiovascular mortality, n (%) 33 (4.8)
Cerebrovascular accident, n (%) 23 (3.3)
Major stroke, n (%) 17 (2.5)
Minor stroke, n (%) 4 (0.6)
TIA, n (%) 2 (0.3)
Myocardial infarction, n (%) 3 (0.4)
Spontaneous myocardial infarction, n (%) 1 (0.2)
Bleeding, n (%) 114 (16.6)
Life-threatening bleeding, n (%) 43 (6.3)
Major bleeding, n (%) 58 (8.4)
Minor bleeding, n (%) 13 (1.9)
Permanent pacemaker implanted, n (%) 140 (20.5)
Table 2 and Online Table 3. Clinical outcomes at 30 days of follow-
up are summarised in Table 5. There were no differences with 
regard to cerebrovascular accidents, myocardial infarction, acute 
kidney injury and life-threatening bleeding complications between 
surgical access and transvascular patients; however, vascular 
access-site and access-related complications (0.7% vs. 14.7%; 
HRadjusted 0.05, 95% CI: 0.01-0.35) as well as major bleeding com-
plications (3.7% vs. 9.6%; HRadjusted 0.33, 95% CI: 0.13-0.84) were 
found to be less frequent among surgical access patients. The 
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increased rate of permanent pacemaker implantation between surgi-
cal access and transvascular treated patients (10.5% vs. 22.9%; 
HRadjusted 0.41, 95% CI: 0.23-0.72) is mainly explained by differ-
ences in device type and design, as permanent pacemaker implanta-
tion was found to be less frequent with the Edwards SAPIEN XT 
when compared with the Medtronic CoreValve. Furthermore, 
patients with surgical access were at higher risk of death after 30 
days compared to patients treated by the transvascular route 
(Figure 2; 9.5% vs. 3.6%; HRadjusted 2.39, 95% CI: 1.13-5.04).
Comparison of the two most frequently used devices using the 
transfemoral access only: clinical outcomes at 30 days according to 
device type are summarised in Table 6. No differences were 
observed with regard to major cardiac and cerebrovascular events 
(Figure 3). However, there was an increased risk of vascular access-
site complications when using the Edwards SAPIEN XT prosthesis 
(19.8% vs. 11.1%; HR 1.80, 95% CI: 1.16-2.76), which was mainly 
due to major vascular complications (11.7% vs. 5.6%; HR 2.12, 
95% CI: 1.17-3.84). In this patient population, there was no rela-
tionship between device size and vascular access-site complica-
tions among patients receiving the Edwards SAPIEN XT prosthesis 
(Online Table 4). In contrast, permanent pacemaker implantation 
was more frequently required after the implantation of the 
Medtronic CoreValve prosthesis (11.4% vs. 31.3%; HR 0.33, 95% 
CI: 0.21-0.51).
Additional subgroup analyses revealed a trend of a higher overall 
mortality among patients undergoing urgent TAVI in comparison 
with elective procedures (Online Table 5-Online Table 7). Moreover, 
9.5%
3.6%
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Figure 2. Cumulative incidence of all-cause mortality among 
patients undergoing TAVI according to type of access at 30-day 
follow-up. Of note, surgical access interventions include transapical 
and direct aortic access patients, and transvascular interventions 
include transfemoral and subclavian access patients.
Table 5. Clinical outcomes of surgical and transvascular access patients at 30 days.
 
Surgical access
N=138
Transvascular
N=559
Crude HR or RR 
(95% CI)
p-value Adjusted HR 
(95% CI)
p-value
Mortality, n (%) 13 (9.5) 20 (3.6) 2.68 (1.33-5.38) 0.006 2.39 (1.13-5.04) 0.022
Cardiovascular mortality, n (%) 13 (9.5) 20 (3.6) 2.68 (1.33-5.38) 0.006 2.39 (1.13-5.04) 0.022
Cerebrovascular accident, n (%) 5 (3.7) 18 (3.2) 1.14 (0.42-3.06) 0.80 1.11 (0.39-3.18) 0.85
Major stroke, n (%) 5 (3.7) 12 (2.2) 1.70 (0.60-4.82) 0.32 1.66 (0.54-5.06) 0.37
Minor stroke, n (%) 0 (0.0) 4 (0.7) 0.45 (0.02-8.31) 1.00
TIA, n (%) 0 (0.0) 2 (0.4) 0.81 (0.04-16.78) 1.00
Myocardial infarction, n (%) 1 (0.7) 2 (0.4) 2.06 (0.19-22.68) 0.56 1.46 (0.11-18.89) 0.77
Acute kidney injury, n (%) 10 (7.4) 40 (7.3) 1.03 (0.51-2.06) 0.94 0.94 (0.46-1.94) 0.87
Stage 1, n (%) 4 (3.0) 22 (4.0) 0.74 (0.26-2.16) 0.59 0.72 (0.24-2.15) 0.55
Stage 2, n (%) 3 (2.2) 4 (0.7) 3.08 (0.69-13.78) 0.14 2.79 (0.55-14.11) 0.22
Stage 3, n (%) 3 (2.2) 14 (2.5) 0.88 (0.25-3.06) 0.84 0.75 (0.21-2.74) 0.66
Bleeding, n (%) 16 (11.8) 98 (17.7) 0.65 (0.38-1.10) 0.11 0.63 (0.37-1.10) 0.10
Life-threatening bleeding, n (%) 10 (7.4) 33 (6.0) 1.24 (0.61-2.51) 0.55 1.46 (0.70-3.04) 0.32
Major bleeding, n (%) 5 (3.7) 53 (9.6) 0.38 (0.15-0.94) 0.037 0.33 (0.13-0.84) 0.02
Minor bleeding, n (%) 1 (0.7) 12 (2.2) 0.34 (0.04-2.62) 0.30 0.31 (0.04-2.46) 0.23
Vascular access-site complications, n (%) 1 (0.7) 82 (14.7) 0.05 (0.01-0.35) 0.003 0.05 (0.01-0.35) 0.003
Major vascular complications, n (%) 0 (0.0) 45 (8.1) 0.04 (0.00-0.65) <0.001
Minor vascular complications, n (%) 1 (0.7) 38 (6.8) 0.11 (0.01-0.78) 0.027 0.12 (0.02-0.89) 0.038
Permanent pacemaker implantation, n (%) 14 (10.5) 126 (22.9) 0.43 (0.25-0.74) 0.003 0.41 (0.23-0.72) 0.002
patients receiving more than one prosthesis had a comparable outcome 
apart from a higher incidence of bleeding (Online Table 8-Online 
Table 10). Finally, patients discharged directly home (28% of the 
overall patient population) had very low event rates up to 30 days 
(mortality: 0%, myocardial infarction: 0.5%, cerebrovascular 
events: 0.5%) (Online Table 11-Online Table 13).
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outcomes with lower mortality rates than predicted with the 
logistic EuroSCORE and the STS risk score.
– Comparison of different access routes suggests a higher risk of 
all-cause mortality via the transapical or transaortic route even in 
an adjusted analysis.
– A comparative analysis between the most frequently used devices 
(Medtronic CoreValve and the Edwards SAPIEN XT) demon-
strates no significant difference with respect to mortality, major 
cardiac or cerebrovascular events. However, there was a three-
fold increased risk of permanent pacemaker implantation for the 
Medtronic CoreValve and an almost twofold increased risk of 
vascular access-site and access-related complications among 
patients receiving the Edwards SAPIEN XT bioprosthesis.
In this first analysis of the Swiss TAVI registry, the overall 
30-day mortality rate remains below the estimated risk using the 
two most frequently used risk scores for the evaluation of TAVI 
patients. With an estimated risk of mortality of 8.2% according to 
the STS score and 20.2% according to the logistic EuroSCORE, 
the risk of TAVI patients in Switzerland is comparable to other 
European or national registries11-14, and confirms the overes-
timation of periprocedural risk for patient selection in contem-
porary clinical practice. While the STS score is currently used 
as the standard risk assessment tool in TAVI trials, the discrep-
ancy between the estimated risk and the observed rate of mortal-
ity after a TAVI procedure is still remarkable and highlights the 
urgent need for a dedicated TAVI risk score for appropriate patient 
selection.
Discussion
This first report of the Swiss TAVI investigators provides detailed 
information on in-hospital and 30-day clinical outcomes. The main 
findings are:
– Carefully selected patients undergoing TAVI with different 
devices and access routes showed favourable short-term clinical 
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2.8%
HR (95% CI)=1.73 (0.72-4.17)
p=0.224
10
8
6
4
2
0
0 5 10 15 20 25 30
Edwards SAPIEN XT
Medtronic CoreValve
Days since TAVI
M
or
ta
lit
y 
(a
t 
3
0
 d
ay
s)
 (
%
)
Patients at risk
CoreValve 324 317 313 312 308 307 295
Edwards
SAPIEN XT 232 225 221 218 216 214 209
Figure 3. Cumulative incidence of all-cause mortality among 
patients undergoing transfemoral TAVI according to type of device 
implanted. Medtronic CoreValve and Edwards SAPIEN XT 
prosthesis implantations represent 94.1% of TAVI implantations in 
Switzerland.
Table 6. Clinical outcomes among transfemoral patients according to device selection.
Edwards SAPIEN 
XT bioprosthesis
N=232
Medtronic 
CoreValve
N=324
HR or RR
(95% CI)
p-value
Mortality, n (%) 11 (4.8) 9 (2.8) 1.73 (0.72-4.17) 0.22
Cardiovascular mortality, n (%) 11 (4.8) 9 (2.8) 1.73 (0.72-4.17) 0.22
Cerebrovascular accident, n (%) 9 (3.9) 9 (2.8) 1.41 (0.56-3.55) 0.47
Major stroke, n (%) 7 (3.0) 5 (1.5) 1.97 (0.62-6.19) 0.25
Minor stroke, n (%) 1 (0.4) 3 (0.9) 0.47 (0.05-4.51) 0.51
TIA, n (%) 1 (0.4) 1 (0.3) 1.41 (0.09-22.48) 0.81
Myocardial infarction, n (%) 0 (0.0) 2 (0.6) 0.28 (0.01-5.81) 0.51
Acute kidney injury, n (%) 14 (6.1) 26 (8.1) 0.76 (0.40-1.46) 0.41
Stage 1, n (%) 8 (3.5) 14 (4.4) 0.81 (0.34-1.92) 0.63
Stage 2, n (%) 1 (0.4) 3 (0.9) 0.47 (0.05-4.53) 0.51
Stage 3, n (%) 5 (2.2) 9 (2.8) 0.78 (0.26-2.34) 0.66
Bleeding, n (%) 39 (17.0) 58 (18.1) 0.95 (0.63-1.42) 0.80
Life-threatening bleeding, n (%) 12 (5.2) 21 (6.6) 0.80 (0.39-1.62) 0.54
Major bleeding, n (%) 26 (11.4) 27 (8.4) 1.38 (0.80-2.36) 0.24
Minor bleeding, n (%) 1 (0.4) 10 (3.1) 0.14 (0.02-1.09) 0.06
Vascular access-site and access-related complications, n (%) 46 (19.8) 36 (11.1) 1.80 (1.16-2.78) 0.008
Major vascular complications, n (%) 27 (11.7) 18 (5.6) 2.12 (1.17-3.84) 0.014
Minor vascular complications, n (%) 20 (8.6) 18 (5.6) 1.55 (0.82-2.93) 0.18
Permanent pacemaker implanted, n (%) 26 (11.4) 100 (31.3) 0.33 (0.21-0.51) <0.001
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All deaths within the first 30 days after TAVI were adjudicated to 
be due to cardiovascular causes, and the rate of 4.8% compares 
favourably to the large-scale CoreValve ADVANCE study (4.6%, 
30-day all-cause mortality)14 and the Source registry (8.5%, 30-day 
all-cause mortality)13, which are considered high-quality databases 
of contemporary TAVI experience with second-generation devices. 
While no significant difference was observed for all-cause mortal-
ity between the Edwards SAPIEN XT and the Medtronic CoreValve 
in the transfemoral cohort, there was a significantly higher risk for 
mortality among patients undergoing TAVI via a surgical access 
route. This observation was independent of baseline confounders 
and is consistent with previous reports from the Source registry 
(transfemoral vs. transapical 4.3% vs. 9.9%)13, the France 2 registry 
(transfemoral vs. transapical 8.5% vs. 13.9%, p<0.001)11 and the 
UK TAVI registry (transfemoral vs. other routes 5.5% vs. 10.7%, 
p=0.006)12. The reason for this difference is unclear, but is most 
probably related to the higher risk of patients in the surgical access 
group. Notably, the majority of TAVI centres in Switzerland follow 
a “transfemoral first” strategy and the transapical access remains 
second choice only for patients not eligible to be treated via a trans-
femoral access. Knowing this, a substantial selection bias to the 
disadvantage of transapical patients might be mirrored in the results 
of this report.
The incidence of cerebrovascular accidents in the periprocedural 
phase after TAVI was comparable to rates reported in other reg-
istries. In Germany, periprocedural stroke after TAVI is reported 
with an incidence rate of 1.7 to 2.3%15, whereas the stroke rates 
amounted to 3.4% in France11, 4.1% in the UK (in-hospital)12, and 
5% in Belgium16. In contrast to a recent meta-analysis with more 
than 10,000 TAVI patients, indicating a decrease in cerebrovascu-
lar accidents among patients undergoing transapical TAVI (2.7% 
vs. 4.2%)17, the periprocedural stroke rate was similar among sur-
gical access and transvascular patients in our patient population. 
A 30-day rate of 3.3% of cerebrovascular accidents still appears 
relatively high and requires further action to minimise this risk. 
Technological improvement, more standardised procedural tech-
niques and cerebral protection during the procedure may help in 
reducing these disabling adverse events. However, recent studies 
evaluating cerebral protection devices have so far failed to demon-
strate a beneficial effect18. Last but not least, alternative antiplatelet 
and anticoagulation regimens (e.g., bivalirudin) might also be of 
help in this regard.
In this patient population, the Medtronic CoreValve was asso-
ciated with a higher risk for permanent pacemaker implantation 
compared with the Edwards SAPIEN XT prosthesis, corroborat-
ing previous reports. Conversely, more vascular access-site com-
plications were observed with the use of the Edwards SAPIEN XT 
as compared with the Medtronic CoreValve without differences in 
terms of bleeding. The latter observation is difficult to explain but 
is possibly related to the larger sheath size (outer diameter) when 
using the Edwards SAPIEN XT. Other confounding factors like ves-
sel quality, tortuosity and calcification might also have contributed 
to this difference. Most importantly, the difference in permanent 
pacemaker implantation or vascular access-site complications did 
not translate into a higher risk of mortality.
Limitations
Several limitations need to be acknowledged before interpreting 
the results of this study. First, as the Swiss TAVI registry was 
designed to generate data on contemporary clinical practice and 
outcomes with newer-generation devices in Switzerland, there is 
no information on the learning curve or the evolution of TAVI 
devices, procedures or outcomes over time. Second, clinical prac-
tice and expertise might be different in the participating centres. 
Finally, serious adverse event reporting within Swiss TAVI is left 
to the discretion of each centre and, although the monitoring pro-
cess includes a systematic plausibility and inconsistency check, 
we are not able to exclude a certain underreporting of events and 
bias.
Conclusion
The Swiss TAVI registry is a prospective, national cohort study 
assessing clinical outcomes of consecutive patients undergoing 
TAVI in Switzerland. This first report based on adjudicated events 
shows favourable short-term clinical outcomes in unselected TAVI 
patients.
Impact on daily practice
The Swiss TAVI registry provides favourable clinical outcomes 
and reflects contemporary clinical practice with CE-approved 
TAVI devices in patients carefully selected by the Heart Team. 
The transfemoral route was the preferred access for the majority 
of patients and was associated with low rates of mortality and 
cerebrovascular events. However, further improvement of the 
technology is required to reduce the rate of vascular access-site 
and bleeding complications.
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Online data supplement
Online Appendix. Collaborators and Swiss TAVI Investigators
University Hospital Basel
Department of Cardiology: Raban Jeger, MD; Christoph Kaiser, MD
Department of Cardiothoracic Surgery: Oliver Reuthebuch, MD
University Hospital Bern
Department of Cardiology: Peter Wenaweser, MD; Stefan 
Stortecky, MD; Lorenz Räber, MD; Stephan Windecker, MD; 
Saskia Dunkel de-Raad, PhD
Department of Cardiothoracic Surgery: Christoph Huber, MD; 
Thierry Carrel, MD
Department of Clinical Research
Clinical Trials Unit, University of Bern: Peter Jüni, MD; Dik Heg, 
PhD; Nico Pfäffli; Serge Zaugg
University Hospital Geneva
Department of Cardiology: Marco Roffi, MD; Stephane Noble, MD
Department of Cardiothoracic Surgery: Mustafa Cikirikcioglu, MD
University Hospital Lausanne
Department of Cardiology: Didier Locca, MD
Department of Cardiothoracic Surgery: Enrico Ferrari, MD
Cantonal Hospital Lucerne
Department of Cardiology: Stefan Toggweiler, MD
Department of Cardiothoracic Surgery: Xavier Mueller, MD
Cardiocentro Ticino, Lugano
Department of Cardiology: Giovanni Pedrazzini, MD
Department of Cardiothoracic Surgery: Stefano Demertzis, MD
Triemli Hospital Zurich
Department of Cardiology: David Tüller, MD; Franz Eberli, MD
Department of Cardiothoracic Surgery: Michele Genoni, MD; 
Omer Dzemali, MD
Hirslanden Clinic Zurich
Klinik im Park
Department of Cardiology: Franz W. Amann, MD
Department of Cardiothoracic Surgery: Pascal A. Berdat, MD
Hirslanden Cardiac Centre Zurich
Department of Cardiology: Gabor Sütsch, MD
Department of Cardiothoracic Surgery: Franziska Bernet, MD
Heart Clinic Hirslanden
Department of Cardiology: Roberto Corti, MD
Department of Cardiothoracic Surgery: Jürg Grünenfelder, MD
University Hospital Zurich
Department of Cardiology: Fabian Nietlispach, MD; Ronald 
Binder, MD
Department of Cardiothoracic Surgery: Volkmar Falk, MD; 
Francesco Maisano, MD
Department of Anaesthesiology: Dominique Bettex, MD
St Clara’s Hospital Basel
Department of Cardiology: Lukas Altwegg, MD (prior member of 
the SC)
Online Table 1. In-hospital clinical outcomes.
In-hospital clinical outcomes
All patients 
N=697
Mortality, n (%) 22 (3.2)
Cardiovascular mortality, n (%) 22 (3.2)
Cerebrovascular accident, n (%) 22 (3.2)
Major stroke, n (%) 17 (2.4)
Minor stroke, n (%) 3 (0.4)
TIA, n (%) 2 (0.3)
Myocardial infarction, n (%) 2 (0.3)
Periprocedural myocardial infarction, n (%) 2 (0.3)
Acute kidney injury, n (%) 49 (7.0)
Stage 1, n (%) 26 (3.7)
Stage 2, n (%) 7 (1.0)
Stage 3, n (%) 16 (2.3)
Bleeding, n (%) 105 (15.1)
Life-threatening bleeding, n (%) 37 (5.3)
Major bleeding, n (%) 56 (8.0)
Minor bleeding, n (%) 12 (1.7)
Vascular access-site and access-related 
complications, n (%) 82 (11.8)
Major vascular complications, n (%) 44 (6.3)
Minor vascular complications, n (%) 39 (5.6)
Permanent pacemaker implanted, n (%) 137 (19.7)
Depicted are number of first events with % of all patients (in-hospital 
events). All clinical outcomes were adjudicated.
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Online Table 2. Baseline surgical vs. transvascular access.
Baseline characteristics of surgical access vs. transvascular access 
patients
Surgical access 
N=138
Transvascular 
N=559
Difference 
(95% CI)
p-value
Age (years) 81.6±5.8 82.6±6.2 –1.0 (–2.2; 0.2) 0.088
Female gender, n (%) 66 (47.8%) 293 (52.4%) –4.6% (–13.9%; 4.7%) 0.34
Body mass index (kg/m2) 26.2±4.8 26.3±5.0 –0.14 (–1.1; 0.8) 0.76
Cardiac risk 
factors
Diabetes mellitus, n (%) 42 (30.4%) 162 (29.0%) –1.5% (–10.0%; 7.0%) 0.75
Dyslipidaemia, n (%) 80 (58.0%) 307 (54.9%) –3.1% (–12.3%; 6.2%) 0.57
Hypertension, n (%) 119 (86.2%) 455 (81.4%) –4.8% (–12.0%; 2.3%) 0.21
Past medical 
history
Previous pacemaker implantation, n (%) 11 (8.0%) 58 (10.4%) 2.4% (–3.2%; 8.0%) 0.52
Previous myocardial infarction, n (%) 22 (15.9%) 83 (14.8%) –1.1% (–7.8%; 5.6%) 0.79
Previous cardiac surgery, n (%) 34 (24.6%) 70 (12.5%) –12.1% (–18.7%; –5.5%) 0.001
Previous stroke, n (%) 17 (12.3%) 66 (11.8%) –0.5% (–6.6%; 5.5%) 0.88
Clinical features Peripheral vascular disease, n (%) 58 (42.0%) 79 (14.1%) –27.9% (–35.0%; –20.8%) <0.001
Chronic obstructive pulmonary disease, n (%) 25 (18.1%) 84 (15.0%) –3.1% (–9.9%; 3.7%) 0.36
Coronary artery disease, n (%) 96 (69.6%) 294 (52.6%) –17.0% (–26.2%; –7.8%) <0.001
Left ventricular ejection fraction (%) 52.4±14.3 54.2±14.1 –1.88 (–5.0; 1.2) 0.23
Aortic valve area (cm2) 0.7±0.3 0.74±0.3 –0.01 (–0.07; 0.05) 0.70
Mean transaortic gradient (mmHg) 45.5±19.8 44.7±16.7 0.82 (–2.97; 4.61) 0.67
Risk assessment Log. EuroSCORE (%) 22.5±13.1 19.6±12.5 2.89 (0.13; 5.66) 0.04
STS score (%) 9.0±7.8 8.0±7.0 0.92 (–0.41; 2.25) 0.18
Depicted are means with standard deviations (p-value from t-tests) or counts (% of all patients; p-value from Fisher’s or chi-square tests).
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Online Table 3. Procedure surgical vs. transvascular access.
Procedural characteristics surgical access vs. transvascular access patients
Surgical access
N=138
Transvascular
N=559
Difference
(95% CI)
p-value
Procedure time (min) 83.3±41.4 73.9±36.8 9.4 (2.2; 16.6) 0.011
Amount of contrast (ml) 192.0±91.2 220.0±110 –28.0 (–49.4; –6.6) 0.010
General anaesthesia, n (%) 138 (100.0%) 242 (43.4%) 56.6% (48.3%; 64.9%) <0.001
Procedure location <0.001
Catheterisation laboratory, n (%) 95 (68.8%) 425 (76.0%) –7.2% (–15.3%; 0.9%)
Operating room, n (%) 7 (5.1%) 1 (0.2%) 4.9% (2.9%; 6.9%)
Hybrid room, n (%) 36 (26.1%) 133 (23.8%) 2.3% (–5.7%; 0.3%)
Concomitant procedure
Percutaneous coronary intervention, n (%) 7 (5.1%) 58 (10.4%) 5.3% (–0.1%; 10.7%) 0.071
Device features
Prior balloon aortic valvuloplasty, n (%) 129 (93.5%) 475 (85.0%) –8.5% (–14.8%; –2.2%) 0.008
Device implanted <0.001
Medtronic CoreValve, n (%) 12 (8.8%) 324 (58.2%) –49.4% (–58.0%; –40.8%)
Edwards SAPIEN XT, n (%) 85 (62.0%) 232 (41.7%) 20.4% (11.2%; 29.6%)
Symetis Acurate, n (%) 17 (12.4%) 0 (0.0%) 12.4% (9.7%; 15.2%)
JenaValve, n (%) 23 (16.8%) 0 (0.0%) 16.8% (13.7%; 19.9%)
SJM Portico, n (%) 0 (0.0%) 1 (0.2%) –0.2% (–0.9%; 0.5%)
Aortic regurgitation post TAVI 0.24
Grade 0, n (%) 40 (29.6%) 130 (23.8%) 5.9% (–2.3%; 14.0%)
Grade 1, n (%) 88 (65.2%) 364 (66.5%) –1.4% (–10.3%; 7.6%)
Grade 2, n (%) 6 (4.4%) 49 (9.0%) –4.5% (–9.6%; 0.6%)
Grade 3, n (%) 1 (0.7%) 4 (0.7%) 0.0% (–1.6%; 1.6%)
In-hospital course
Permanent pacemaker implantation, n (%) 12 (8.8%) 125 (22.7%) 13.9% (6.5%; 21.4%) <0.001
Any packed red blood cell infusion during hospitalisation, 
n (%) 36 (26.1%) 95 (17.1%) –9.0% (–16.3%; –1.7%) 0.021
Number of PRBC, median (interquartile range) 2.0 (1.0; 3.0) 2.0 (1.0; 3.0) –0.58 (–2.05; 0.89) 0.51
Overall in-hospital stay after TAVI (days) 11.1±5.1 10.6±6.4 0.48 (–0.68; 1.63) 0.42
Stay at intensive care unit (days) 2.0±1.9 0.9±2.4 1.03 (0.59; 1.46) <0.001
Stay at intermediate care (days) 1.1±2.4 2.9±3.0 –1.75 (–2.29; –1.22) <0.001
Stay at general ward (days) 8.1±4.4 6.9±5.5 1.20 (0.20; 2.20) 0.019
Patient discharged to 0.001
Home, n (%) 30 (22.2%) 167 (30.6%) –8.4% (–16.9%; 0.2%)
Referring hospital, n (%) 23 (17.0%) 141 (25.8%) –8.8% (–16.8%; –0.7%)
Rehabilitation clinic, n (%) 74 (54.8%) 222 (40.7%) 14.2% (4.8%; 23.5%)
Nursing home, n (%) 0 (0.0%) 6 (1.1%) –1.1% (–2.9%; 0.7%)
Other, n (%) 8 (5.9%) 10 (1.8%) 4.1% (1.1%; 7.1%)
Depicted are means with standard deviations (p-values from ANOVAs) or counts (% of all patients; p-values from chi-square tests). 
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Online Table 4. Access complications according to Edwards SAPIEN XT size.
Vascular access-site complications according to device size among transfemoral access patients with the Edwards SAPIEN XT prosthesis
23 mm
N=68
26 mm
N=142
29 mm
N=21
HR 
(95% CI)
p-value
30-day follow-up - events
Vascular access-site complications, n (%) 14 (20.6) 29 (20.4) 3 (14.3) 0.90 (0.55-1.47) 0.67
Major vascular complications, n (%) 7 (10.3) 18 (12.7) 2 (9.5) 1.05 (0.55-2.00) 0.88
Minor vascular complications, n (%) 7 (10.3) 12 (8.5) 1 (4.8) 0.75 (0.35-1.60) 0.46
Depicted are number of first events censored at 30 days since procedure with % from Kaplan-Meier estimates. *n: 1 patient with Edwards device size of 
20 mm not shown. Hazard ratio (HR; with 95% confidence intervals) from Cox’s regression with a p-value testing a linear effect from 23 mm (set as 
reference) to 29 mm.
Online Table 5. Baseline urgent vs. elective treatment.
Baseline characteristics of urgent vs. elective patients
Urgent 
N=35
Elective 
N=657
Difference 
(95% CI)
p-value
Age (years) 82.6±6.0 82.4±6.2 0.2 (–1.9; 2.3) 0.85
Female gender, n (%) 19 (54.3%) 338 (51.4%) 2.8% (–14.2%; 19.9%) 0.86
Body mass index (kg/m2) 26.0±5.2 26.4±5.0 –0.3 (–2.0; 1.4) 0.70
Cardiac risk 
factors
Diabetes mellitus, n (%) 12 (34.3%) 192 (29.2%) –5.1% (–20.6%; 10.5%) 0.57
Dyslipidaemia, n (%) 19 (54.3%) 366 (55.7%) 1.4% (–15.5%; 18.4%) 0.86
Hypertension, n (%) 28 (80.0%) 542 (82.5%) 2.5% (–10.5%; 15.5%) 0.65
Past medical 
history
Previous pacemaker implantation, n (%) 1 (2.9%) 67 (10.2%) 7.3% (–2.8%; 17.5%) 0.24
Previous myocardial infarction, n (%) 6 (17.1%) 98 (14.9%) –2.2% (–14.4%; 10.0%) 0.63
Previous cardiac surgery, n (%) 3 (8.6%) 101 (15.4%) 6.8% (–5.4%; 19.0%) 0.34
Previous stroke, n (%) 3 (8.6%) 80 (12.2%) 3.6% (–7.5%; 14.7%) 0.79
Clinical features Peripheral vascular disease, n (%) 5 (14.3%) 130 (19.8%) 5.5% (–8.0%; 19.0%) 0.52
Chronic obstructive pulmonary disease, n (%) 4 (11.4%) 103 (15.7%) 4.2% (–8.1%; 16.6%) 0.64
Coronary artery disease, n (%) 24 (68.6%) 365 (55.6%) –13.0% (–29.9%; 3.9%) 0.16
Left ventricular ejection fraction (%) 46.9±17.6 54.2±13.8 –7.4 (–12.9; –1.8) 0.01
Aortic valve area (cm2) 0.7±0.2 0.7±0.3 –0.06 (–0.17; 0.04) 0.22
Mean transaortic gradient (mmHg) 44.1±18.6 44.8±17.4 –0.7 (–7.6; 6.2) 0.84
Risk assessment Log. EuroSCORE (%) 29.2±19.8 19.4±11.6 9.8 (5.5; 14.0) <0.001
STS score (%) 12.1±9.7 8.0±6.9 4.1 (1.7; 6.5) 0.001
Depicted are means with standard deviations (p-value from t-tests) or counts (% of all patients; p-value from Fisher’s or chi-square tests). In n: 5 
patients the indication urgent/elective was missing and they were excluded from the analyses.
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Online Table 6. Procedure urgent vs. elective treatment.
Procedural characteristics of urgent vs. elective patients
Urgent N=35 Elective N=657 Difference (95% CI) p-value
Procedure time (min) 76.3±31.0 76.0±38.2 0.4 (–14.0; 14.8) 0.96
Amount of contrast (ml) 221.1±87.8 214.4±108.4 6.7 (–31.5; 45.0) 0.73
General anaesthesia, n (%) 11 (31.4%) 365 (55.6%) –24.2% (–41.1%; –7.3%) 0.008
Conversion from local to general anaesthesia, n (%) 3 (12.5%) 13 (4.5%) –8.0% (–17.2%; 1.1%) 0.11
Procedure location 0.007
Catheterisation laboratory, n (%) 34 (97.1%) 481 (73.2%) 23.9% (9.2%; 38.7%)
Operating room, n (%) 0 (0.0%) 8 (1.2%) –1.2% (–4.9%; 2.4%)
Hybrid room, n (%) 1 (2.9%) 168 (25.6%) –22.7% (–37.3%; –8.2%)
Access-site location 0.67
Femoral 30 (85.7%) 517 (78.7%) 7.0% (–6.8%; 20.9%)
Transapical 5 (14.3%) 120 (18.3%) –4.0% (–17.1%; 9.1%)
Subclavian 0 (0.0%) 8 (1.2%) –1.2 (–4.9%; 2.4%)
Direct aortic 0 (0.0%) 12 (1.8%) –1.8% (–6.3%; 2.6%)
Concomitant procedure
Percutaneous coronary intervention, n (%) 7 (20.0%) 57 (8.7%) –11.3% (–21.2%; –1.5%) 0.035
Device features
Prior balloon aortic valvuloplasty, n (%) 31 (88.6%) 568 (86.5%) –2.1% (–13.8%; 9.5%) 1.00
Device implanted 0.56
Medtronic CoreValve, n (%) 18 (51.4%) 314 (48.0%) 3.4% (–13.6%; 20.5%)
Edwards SAPIEN XT, n (%) 15 (42.9%) 301 (46.0%) –3.2% (–20.2%; 13.8%)
Symetis Acurate, n (%) 2 (5.7%) 15 (2.3%) 3.4% (–1.9%; 8.7%)
JenaValve, n (%) 0 (0.0%) 23 (3.5%) –3.5% (–9.6%; 2.6%)
SJM Portico, n (%) 0 (0.0%) 1 (0.2%) –0.2% (–1.5%; 1.1%)
Aortic regurgitation post TAVI 0.96
Grade 0, n (%) 8 (22.9%) 161 (25.1%) –2.2% (–17.0%; 12.5%)
Grade 1, n (%) 24 (68.6%) 425 (66.2%) 2.4% (–13.8%; 18.5%)
Grade 2, n (%) 3 (8.6%) 52 (8.1%) 0.5% (–8.9%; 9.8%)
Grade 3, n (%) 0 (0.0%) 4 (0.6%) –0.6% (–3.2%; 2.0%)
In-hospital course
Permanent pacemaker implantation, n (%) 4 (11.4%) 133 (20.4%) 8.9% (–4.7%; 22.5%) 0.28
Any packed red blood cell during hospitalisation, n (%) 11 (31.4%) 116 (17.8%) –13.7% (–26.9%; –0.5%) 0.069
Number of PRBC, median (interquartile range) 1.0 (1.0; 3.0) 2.0 (1.0; 3.0) –1.1 (–3.7; 1.5) 0.11
Overall in-hospital stay after TAVI (days) 12.7±9.3 10.6±5.9 2.0 (–0.06; 4.1) 0.057
Stay at intensive care unit (days) 1.5±2.6 1.1±2.3 0.4 (–0.5; 1.2) 0.39
Stay at intermediate care (days) 3.5±4.1 2.5±2.9 0.9 (–0.08; 1.9) 0.072
Stay at general ward (days) 7.8±8.8 7.1±5.1 0.8 (–1.1; 2.6) 0.41
Patient discharged to <0.001
Home, n (%) 6 (18.2%) 191 (29.5%) –11.3% (–27.2%; 4.6%)
Referring hospital, n (%) 14 (42.4%) 150 (23.1%) 19.3% (4.3%; 34.2%)
Rehabilitation clinic, n (%) 9 (27.3%) 287 (44.3%) –17.0% (–34.4%; 0.3%)
Nursing home, n (%) 0 (0.0%) 6 (0.9%) –0.9% (–4.2%; 2.4%)
Other, n (%) 4 (12.1%) 14 (2.2%) 10.0% (4.4%; 15.5%)
Depicted are means with standard deviations (p-values from ANOVAs) or counts (% of all patients; p-values from chi-square tests). In n: 5 patients the 
indication urgent/elective was missing and they were excluded from the analyses.
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Online Table 7. Outcomes urgent vs. elective treatment.
Clinical outcomes of urgent vs. elective patients
Urgent 
N=35
Elective 
N=657
HR or RR 
(95% CI)
p-value Adjusted HR or RR 
(95% CI)
p-value
30-day follow-up - events
Mortality, n (%) 4 (11.6) 29 (4.5) 2.74 (0.96-7.81) 0.058 2.61 (0.91-7.52) 0.075
Cardiovascular mortality, n (%) 4 (11.6) 29 (4.5) 2.74 (0.96-7.81) 0.058 2.61 (0.91-7.52) 0.075
Cerebrovascular accident, n (%) 0 (0.0) 22 (3.4) 0.41 (0.03-6.62) 0.62
Major stroke, n (%) 0 (0.0) 16 (2.4) 0.56 (0.03-9.15) 1.00
Minor stroke, n (%) 0 (0.0) 4 (0.6) 2.06 (0.11-37.52) 1.00
TIA, n (%) 0 (0.0) 2 (0.3) 3.70 (0.18-75.63) 1.00
Myocardial infarction, n (%) 0 (0.0) 3 (0.5) 2.65 (0.14-50.32) 1.00
Acute kidney injury, n (%) 4 (12.2) 45 (7.0) 1.80 (0.65-5.01) 0.26 1.59 (0.57-4.44) 0.38
Stage 1, n (%) 4 (12.2) 21 (3.2) 3.87 (1.33-11.29) 0.013 3.43 (1.16-10.10) 0.026
Stage 2, n (%) 0 (0.0) 7 (1.1) 1.23 (0.07-21.11) 1.00
Stage 3, n (%) 0 (0.0) 17 (2.6) 0.53 (0.03-8.64) 1.00
Bleeding, n (%) 7 (20.5) 103 (15.9) 1.37 (0.64-2.95) 0.42 1.48 (0.68-3.19) 0.32
Life-threatening bleeding, n (%) 3 (8.7) 37 (5.7) 1.60 (0.49-5.18) 0.44 1.60 (0.49-5.23) 0.44
Major bleeding, n (%) 3 (9.0) 55 (8.5) 1.07 (0.34-3.43) 0.90 1.23 (0.38-3.95) 0.73
Minor bleeding, n (%) 1 (3.0) 11 (1.7) 1.85 (0.24-14.29) 0.56 1.76 (0.22-13.79) 0.59
Vascular access-site and access-related 
complications, n (%) 8 (22.9) 73 (11.1) 2.09 (1.01-4.33) 0.048 2.09 (1.00-4.36) 0.05
Major vascular complications, n (%) 3 (8.6) 40 (6.1) 1.42 (0.44-4.60) 0.56 1.38 (0.43-4.51) 0.59
Minor vascular complications, n (%) 5 (14.3) 34 (5.2) 2.76 (1.08-7.06) 0.034 2.91 (1.12-7.53) 0.028
Permanent pacemaker implanted, n (%) 4 (12.4) 136 (21.1) 0.57 (0.21-1.53) 0.26 0.55 (0.20-1.48) 0.24
Depicted are number of first events with % of all patients (in-hospital events); and censored at 30 days since procedure with % from Kaplan-Meier 
estimates (30-day follow-up events). All clinical outcomes were adjudicated, except for pacemaker implantations. Cox’s regression, reports hazard ratio 
(HR; with 95% confidence intervals). Continuity corrected RR (95% CI) with p-value from Fisher’s exact test in case of zero events. Adjusted HR or RR: 
adjusted for age, gender, previous cardiac surgery, peripheral vascular disease, coronary artery disease. In n: 5 patients the indication urgent/elective 
was missing and they were excluded from the analyses.
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Online Table 8. Baseline one vs. more than one prosthesis.
Baseline characteristics comparing patients with one prosthesis vs. 
two or more prostheses
Two or more 
prostheses 
N=30
One prosthesis 
N=667
Difference 
(95% CI)
p-value
Age (years) 81.3±5.5 82.4±6.2 –1.1 (–3.3; 1.2) 0.35
Female gender, n (%) 14 (46.7%) 345 (51.7%) –5.1% (–23.4%; 13.3%) 0.71
Body mass index (kg/m2) 26.5±5.2 26.3±5.0 0.1 (–1.7; 2.0) 0.88
Cardiac risk 
factors
Diabetes mellitus, n (%) 8 (26.7%) 196 (29.4%) 2.7% (–14.0%; 19.4%) 0.84
Dyslipidaemia, n (%) 19 (63.3%) 368 (55.2%) –8.2% (–26.4%; 10.1%) 0.45
Hypertension, n (%) 22 (73.3%) 552 (82.8%) 9.4% (–4.5%; 23.4%) 0.22
Past medical 
history
Previous pacemaker implantation, n (%) 1 (3.3%) 68 (10.2%) 6.9% (–4.1%; 17.8%) 0.35
Previous myocardial infarction, n (%) 3 (10.0%) 102 (15.3%) 5.3% (–7.8%; 18.4%) 0.60
Previous cardiac surgery, n (%) 4 (13.3%) 100 (15.0%) 1.7% (–11.4%; 14.7%) 1.00
Previous stroke, n (%) 5 (16.7%) 78 (11.7%) –5.0% (–16.9%; 6.9%) 0.39
Clinical 
features
Peripheral vascular disease, n (%) 6 (20.0%) 131 (19.6%) –0.4% (–14.9%; 14.2%) 1.00
Chronic obstructive pulmonary disease, n (%) 4 (13.3%) 105 (15.7%) 2.4% (–10.9%; 15.7%) 1.00
Coronary artery disease, n (%) 16 (53.3%) 374 (56.1%) 2.7% (–15.5%; 21.0%) 0.85
Left ventricular ejection fraction (%) 58.9±12.9 53.6±14.1 5.4 (–0.6; 11.3) 0.076
Aortic valve area (cm2) 0.78±0.3 0.74±0.3 0.04 (–0.06; 0.15) 0.42
Mean transaortic gradient (mmHg) 51.8±19.0 44.5±17.3 7.3 (0.0; 14.6) 0.05
Risk 
assessment
Log. EuroSCORE (%) 15.8±8.7 20.4±12.8 –4.6 (–9.8; 0.6) 0.083
STS score (%) 6.4±4.5 8.3±7.2 –1.9 (–4.5; 0.8) 0.16
Depicted are means with standard deviations (p-values from ANOVAs) or counts (% of all patients; p-values from chi-square tests).
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Online Table 9. Procedure one vs. more than one prosthesis.
Procedural characteristics comparing patients with one prosthesis vs. two 
or more prostheses
Two or more 
prostheses N=30
One prosthesis 
N=667
Difference (95% CI) p-value
Procedure time (min) 114.1±65.3 74.1±35.4 40.0 (25.6; 54.1) <0.001
Amount of contrast (ml) 309.5±107.1 210.7±105.5 98.8 (59.4; 138.2) <0.001
General anaesthesia, n (%) 7 (23.3%) 373 (56.0%) –32.7% (–50.8%; –14.6%) 0.001
Conversion from local to general anaesthesia, n (%) 2 (8.7%) 14 (4.8%) –3.9% (–13.3%; 5.4%) 0.33
Procedure location 0.70
Catheterisation laboratory, n (%) 24 (80.0%) 496 (74.4%) 5.6% (–10.3%; 21.6%)
Operating room, n (%) 0 (0.0%) 8 (1.2%) –1.2% (–5.1%; 2.7%)
Hybrid room, n (%) 6 (20.0%) 163 (24.4%) –4.4% (–20.2%; 11.3%)
Access-site location 0.12
Femoral 29 (96.7%) 522 (78.3%) 18.4% (3.5%; 33.3%)
Transapical 1 (3.3%) 125 (18.7%) –15.4% (–29.5%; –1.3%)
Subclavian 0 (0.0%) 8 (1.2%) –1.2% (–5.1%; 2.7%)
Direct aortic 0 (0.0%) 12 (1.8%) –1.8% (–6.6%; 3.0%)
Concomitant procedure
Percutaneous coronary intervention, n (%) 1 (3.3%) 64 (9.6%) 6.3% (–4.4%; 16.9%) 0.35
Device features
Prior balloon aortic valvuloplasty, n (%) 25 (83.3%) 579 (86.8%) 3.5% (–9.0%; 15.9%) 0.58
Device implanted <0.001
Medtronic CoreValve, n (%) 28 (93.3%) 308 (46.4%) 46.9% (28.9%; 65.0%)
Edwards SAPIEN XT, n (%) 2 (6.7%) 315 (47.4%) –40.8% (–58.8%; –22.7%)
Symetis Acurate, n (%) 0 (0.0%) 17 (2.6%) –2.6% (–8.2%; 3.1%)
JenaValve, n (%) 0 (0.0%) 23 (3.5%) –3.5% (–10.0%; 3.1%)
SJM Portico, n (%) 0 (0.0%) 1 (0.2%) –0.2% (–1.5%; 1.2%)
Aortic regurgitation post TAVI 0.23
Grade 0, n (%) 6 (20.0%) 164 (25.2%) –5.2% (–21.0%; 10.7%)
Grade 1, n (%) 19 (63.3%) 433 (66.4%) –3.1% (–20.4%; 14.3%)
Grade 2, n (%) 4 (13.3%) 51 (7.8%) 5.5% (–4.5%; 15.5%)
Grade 3, n (%) 1 (3.3%) 4 (0.6%) 2.7% (–0.4%; 5.8%)
In-hospital course
Permanent pacemaker implantation, n (%) 9 (30.0%) 128 (19.5%) –10.5% (–25.2%; 4.1%) 0.16
Any packed red blood cell during hospitalisation, n (%) 8 (26.7%) 123 (18.6%) –8.1% (–22.5%; 6.2%) 0.34
Number of PRBC, median (interquartile range) 2.0 (1.0; 3.5) 2.0 (1.0; 3.0) 3.9 (1.3; 6.6) 0.82
Overall in-hospital stay after TAVI (days) 13.6±9.7 10.6±5.9 3.0 (0.8; 5.3) 0.01
Stay at intensive care unit (days) 3.0±7.9 1.0±1.7 2.0 (1.1; 2.8) <0.001
Stay at intermediate care (days) 2.6±2.8 2.5±2.9 0.1 (–1.0; 1.2) 0.85
Stay at general ward (days) 8.0±8.6 7.1±5.1 0.9 (–1.0; 2.9) 0.35
Patient discharged to 0.64
Home, n (%) 8 (26.7%) 189 (29.0%) –2.4% (–19.0%; 14.3%)
Referring hospital, n (%) 6 (20.0%) 158 (24.3%) –4.3% (–20.0%; 11.4%)
Rehabilitation clinic, n (%) 14 (46.7%) 282 (43.3%) 3.3% (–14.9%; 21.5%)
Nursing home, n (%) 0 (0.0%) 6 (0.9%) –0.9% (–4.4%; 2.5%)
Other, n (%) 2 (6.7%) 16 (2.5%) 4.2% (–1.7%; 10.1%)
Depicted are means with standard deviations (p-values from ANOVAs) or counts (% of all patients; p-values from chi-square tests).
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Online Table 11. Baseline discharge home vs. others.
Baseline characteristics for patients discharged home vs. others
Home N=197 Others N=500 Difference (95% CI) p-value
Age (years) 81.6±7.1 82.7±5.7 –1.1 (–2.1; –0.1) 0.036
Female gender, n (%) 78 (39.6%) 281 (56.2%) –16.6% (–24.8%; –8.4%) <0.001
Body mass index (kg/m2) 26.6±5.2 26.2±4.9 0.5 (–0.4; 1.3) 0.28
Cardiac risk 
factors
Diabetes mellitus, n (%) 52 (26.4%) 152 (30.4%) 4.0% (–3.5%; 11.5%) 0.31
Dyslipidaemia, n (%) 107 (54.3%) 280 (56.0%) 1.7% (–6.5%; 9.9%) 0.74
Hypertension, n (%) 163 (82.7%) 411 (82.2%) –0.5% (–6.8%; 5.8%) 0.91
Past medical 
history
Previous pacemaker implantation, n (%) 24 (12.2%) 45 (9.0%) –3.2% (–8.1%; 1.8%) 0.21
Previous myocardial infarction, n (%) 29 (14.7%) 76 (15.2%) 0.5% (–5.4%; 6.4%) 0.91
Previous cardiac surgery, n (%) 36 (18.3%) 68 (13.6%) –4.7% (–10.6%; 1.2%) 0.13
Previous stroke, n (%) 15 (7.6%) 68 (13.6%) 6.0% (0.6%; 11.3%) 0.028
Clinical features Peripheral vascular disease, n (%) 37 (18.8%) 100 (20.0%) 1.2% (–5.4%; 7.8%) 0.75
Chronic obstructive pulmonary disease, n (%) 34 (17.3%) 75 (15.0%) –2.3% (–8.3%; 3.7%) 0.49
Coronary artery disease, n (%) 111 (56.3%) 279 (55.8%) –0.5% (–8.8%; 7.7%) 0.93
Left ventricular ejection fraction (%) 55.9±12.4 52.9±14.7 3.0 (0.2; 5.8) 0.034
Aortic valve area (cm2) 0.8±0.3 0.7±0.2 0.1 (0.04; 0.1) 0.001
Mean transaortic gradient (mmHg) 43.0±14.5 45.6±18.5 –2.6 (–6.0; 0.9) 0.14
Risk assessment Log. EuroSCORE (%) 19.3±12.8 20.5±12.6 –1.2 (–3.8; 1.4) 0.36
STS score (%) 7.7±7.2 8.4±7.1 –0.8 (–2.0; 0.4) 0.20
Depicted are means with standard deviations (p-values from ANOVAs) or counts (% of all patients; p-values from chi-square tests). In n: 16 patients the 
discharge location was unclear and assumed others.
Online Table 10. Outcomes one vs. more than one prosthesis.
Clinical outcomes comparing patients with one prosthesis vs. two or more prostheses
Two or more 
prostheses 
N=30
One 
prosthesis 
N=667
HR or RR 
(95% CI)
p-value Adjusted HR 
or RR (95% CI)
p-value
30-day follow-up - events
Mortality, n (%) 2 (6.7) 31 (4.7) 1.48 (0.35-6.18) 0.59 1.71 (0.41-7.17) 0.46
Cardiovascular mortality, n (%) 2 (6.7) 31 (4.7) 1.48 (0.35-6.18) 0.59 1.71 (0.41-7.17) 0.46
Cerebrovascular accident, n (%) 0 (0.0) 23 (3.5) 0.47 (0.03-7.56) 0.62
Major stroke, n (%) 0 (0.0) 17 (2.6) 0.63 (0.04-10.23) 1.00
Minor stroke, n (%) 0 (0.0) 4 (0.6) 2.43 (0.13-44.12) 1.00
TIA, n (%) 0 (0.0) 2 (0.3) 4.38 (0.21-89.27) 1.00
Myocardial infarction, n (%) 0 (0.0) 3 (0.5) 3.13 (0.17-59.26) 1.00
Acute kidney injury, n (%) 2 (6.9) 48 (7.3) 0.95 (0.23-3.91) 0.94 0.96 (0.23-3.94) 0.95
Stage 1, n (%) 2 (6.9) 24 (3.7) 1.92 (0.45-8.12) 0.38 1.89 (0.45-8.02) 0.39
Stage 2, n (%) 0 (0.0) 7 (1.1) 1.46 (0.09-24.98) 1.00
Stage 3, n (%) 0 (0.0) 17 (2.6) 0.63 (0.04-10.23) 1.00
Bleeding, n (%) 9 (30.2) 105 (15.9) 2.07 (1.05-4.09) 0.036 2.08 (1.05-4.13) 0.035
Life-threatening bleeding, n (%) 3 (10.0) 40 (6.1) 1.72 (0.53-5.57) 0.36 1.75 (0.54-5.67) 0.35
Major bleeding, n (%) 4 (13.9) 54 (8.2) 1.70 (0.62-4.71) 0.30 1.66 (0.60-4.63) 0.33
Minor bleeding, n (%) 2 (6.9) 11 (1.7) 4.27 (0.95-19.28) 0.059 4.81 (1.05-21.93) 0.042
Vascular access-site and access-related 
complications, n (%) 6 (20.1) 77 (11.6) 1.74 (0.76-4.00) 0.19 1.78 (0.77-4.09) 0.18
Major vascular complications, n (%) 4 (13.5) 41 (6.2) 2.19 (0.78-6.10) 0.14 2.24 (0.80-6.29) 0.13
Minor vascular complications, n (%) 2 (6.7) 37 (5.5) 1.20 (0.29-4.99) 0.80 1.22 (0.29-5.09) 0.78
Permanent pacemaker implanted, n (%) 9 (31.6) 131 (20.0) 1.65 (0.84-3.24) 0.15 1.64 (0.84-3.23) 0.15
Depicted are number of first events with % of all patients (in-hospital events); and censored at 30 days since procedure with % from Kaplan-Meier 
estimates (30-day follow-up events). All clinical outcomes were adjudicated, except for pacemaker implantations. Cox’s regression, reports hazard ratio 
(HR; with 95% confidence intervals). Continuity corrected RR (95% CI) with p-value from Fisher’s exact test in case of zero events.
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Online Table 12. Procedure discharge home vs. others.
Procedural characteristics for patients discharged home vs. others
Home N=197 Others N=500 Difference (95% CI) p-value
Procedure time (min) 73.3±32.3 76.8±39.9 –3.5 (–9.9; 2.9) 0.29
Amount of contrast (ml) 212.8±103.6 215.9±109.1 –3.1 (–21.3; 15.1) 0.74
General anaesthesia, n (%) 113 (57.4%) 267 (53.5%) 3.9% (–4.4%; 12.1%) 0.40
Conversion from local to general anaesthesia, n (%) 0 (0.0%) 16 (6.9%) 6.9% (1.5%; 12.4%) 0.008
Procedure location
Catheterisation laboratory, n (%) 141 (71.6%) 379 (75.8%) –4.2% (–11.4%; 3.0%)
Operating room, n (%) 2 (1.0%) 6 (1.2%) –0.2% (–1.9%; 1.6%)
Hybrid room, n (%) 54 (27.4%) 115 (23.0%) 4.4% (–2.7%; 11.5%)
Access-site location 0.005
Femoral 161 (81.7%) 390 (78.0%) 3.7% (–3.0%; 10.5%)
Transapical 29 (14.7%) 97 (19.4%) –4.7% (–11.0%; 1.7%)
Subclavian 6 (3.0%) 2 (0.4%) 2.6% (0.9%; 4.4%)
Direct aortic 1 (0.5%) 11 (2.2%) –1.7% (–3.8%; 0.5%)
Concomitant procedure
Percutaneous coronary intervention, n (%) 16 (8.1%) 49 (9.8%) 1.7% (–3.1%; 6.5%) 0.56
Device features
Prior balloon aortic valvuloplasty, n (%) 173 (87.8%) 431 (86.2%) –1.6% (–7.2%; 4.0%) 0.62
Device implanted 0.96
Medtronic CoreValve, n (%) 96 (48.7%) 240 (48.3%) 0.4% (–7.8%; 8.7%)
Edwards SAPIEN, n (%) 90 (45.7%) 227 (45.7%) 0.0% (–8.2%; 8.3%)
Symetis Acurate, n (%) 4 (2.0%) 13 (2.6%) –0.6% (–3.1%; 2.0%)
JenaValve, n (%) 7 (3.6%) 16 (3.2%) 0.3% (–2.6%; 3.3%)
SJM Portico, n (%) 0 (0.0%) 1 (0.2%) –0.2% (–0.8%; 0.4%)
Aortic regurgitation post TAVI 0.018
Grade 0, n (%) 55 (28.2%) 115 (23.6%) 4.6% (–2.6%; 11.8%)
Grade 1, n (%) 133 (68.2%) 319 (65.5%) 2.7% (–5.2%; 10.6%)
Grade 2, n (%) 7 (3.6%) 48 (9.9%) –6.3% (–10.8%; –1.8%)
Grade 3, n (%) 0 (0.0%) 5 (1.0%) –1.0% (–2.4%; 0.4%)
In-hospital course
Permanent pacemaker implantation, n (%) 43 (21.8%) 94 (19.1%) –2.7% (–9.3%; 3.9%) 0.46
Any packed red blood cell during hospitalisation, n (%) 21 (10.7%) 110 (22.2%) 11.5% (5.1%; 17.9%) <0.001
Number of PRBC, median (interquartile range) 2.0 (1.0; 3.5) 2.0 (1.0; 3.0) –0.5 (–2.3; 1.2) 0.74
Overall in-hospital stay after TAVI (days) 9.2±5.0 11.4±6.4 –2.2 (–3.2; –1.2) <0.001
Stay at intensive care unit (days) 0.9±1.2 1.2±2.7 –0.3 (–0.7; 0.1) 0.19
Stay at intermediate care (days) 1.9±2.1 2.8±3.2 –0.9 (–1.4; –0.4) <0.001
Stay at general ward (days) 6.4±4.6 7.4±5.6 –1.0 (–1.9; –0.1) 0.023
Depicted are means with standard deviations (p-values from ANOVAs) or counts (% of all patients; p-values from chi-square tests). In n: 16 patients the 
discharge location was unclear and assumed others.
20
 EuroIntervention 2
0
14
; 9
-online publish-ahead-of-print A
p
ril 2
0
14
Online Table 13. Outcomes discharge home vs. others.
Clinical outcomes comparing patients discharged home vs. others
Home 
N=197
Others 
N=500
HR or RR (95% CI) p-value Adjusted HR or RR 
(95% CI)
p-value
30-day follow-up - events
Mortality, n (%) 0 (0.0) 33 (6.7) 0.04 (0.00-0.65) <0.001
Cardiovascular mortality, n (%) 0 (0.0) 33 (6.7) 0.04 (0.00-0.65) <0.001
Cerebrovascular accident, n (%) 1 (0.5) 22 (4.5) 0.11 (0.02-0.84) 0.033 0.12 (0.02-0.92) 0.041
Major stroke, n (%) 1 (0.5) 16 (3.2) 0.16 (0.02-1.18) 0.072 0.17 (0.02-1.30) 0.088
Minor stroke, n (%) 0 (0.0) 4 (0.8) 0.28 (0.02-5.18) 0.58
TIA, n (%) 0 (0.0) 2 (0.4) 0.51 (0.02-10.58) 1.00
Myocardial infarction, n (%) 1 (0.5) 2 (0.4) 1.24 (0.11-13.66) 0.86 1.15 (0.10-13.14) 0.91
Acute kidney injury, n (%) 12 (6.1) 38 (7.8) 0.78 (0.41-1.50) 0.46 0.76 (0.39-1.46) 0.41
Stage 1, n (%) 9 (4.6) 17 (3.5) 1.33 (0.59-2.98) 0.49 1.22 (0.54-2.76) 0.64
Stage 2, n (%) 1 (0.5) 6 (1.2) 0.41 (0.05-3.41) 0.41 0.52 (0.06-4.43) 0.55
Stage 3, n (%) 2 (1.0) 15 (3.1) 0.33 (0.08-1.44) 0.14 0.31 (0.07-1.38) 0.12
Bleeding, n (%) 19 (9.7) 95 (19.3) 0.48 (0.29-0.79) 0.003 0.49 (0.30-0.81) 0.005
Life-threatening bleeding, n (%) 4 (2.0) 39 (7.9) 0.25 (0.09-0.70) 0.008 0.25 (0.09-0.71) 0.009
Major bleeding, n (%) 11 (5.6) 47 (9.6) 0.58 (0.30-1.11) 0.10 0.61 (0.32-1.19) 0.15
Minor bleeding, n (%) 4 (2.0) 9 (1.8) 1.10 (0.34-3.56) 0.88 1.06 (0.32-3.52) 0.92
Vascular access-site and access-related 
complications, n (%) 12 (6.1) 71 (14.2) 0.43 (0.23-0.78) 0.006 0.46 (0.25-0.84) 0.013
Major vascular complications, n (%) 5 (2.5) 40 (8.0) 0.31 (0.12-0.79) 0.015 0.35 (0.14-0.90) 0.029
Minor vascular complications, n (%) 7 (3.6) 32 (6.4) 0.56 (0.25-1.26) 0.16 0.57 (0.25-1.30) 0.18
Permanent pacemaker implanted, n (%) 43 (21.9) 97 (19.9) 1.11 (0.78-1.59) 0.56 1.02 (0.71-1.47) 0.90
Depicted are number of first events with % of all patients (in-hospital events); and censored at 30 days since procedure with % from Kaplan-Meier 
estimates (30-day follow-up events). All clinical outcomes were adjudicated, except for pacemaker implantations. Cox’s regression, reports hazard ratio 
(HR; with 95% confidence intervals). Continuity corrected RR (95% CI) with p-value from Fisher’s exact test in case of zero events. In n: 16 patients 
the discharge location was unclear and assumed others.
